药品注册申请号:013025
申请类型:NDA (新药申请)
申请人:HOSPIRA
申请人全名:HOSPIRA INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 THAM-E POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE INJECTABLE;INJECTION 370MG/VIAL;1.75GM/VIAL;36GM/VIAL No No None 1965/12/16 Approved Prior to Jan 1, 1982 Discontinued
002 THAM TROMETHAMINE SOLUTION;INJECTION 18GM/500ML (3.6GM/100ML) Yes Yes None Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2013/11/08 SUPPL-55(补充) Approval Manufacturing (CMC) PRIORITY
2013/06/25 SUPPL-54(补充) Approval Manufacturing (CMC) PRIORITY
2006/07/20 SUPPL-40(补充) Approval Manufacturing (CMC) N/A
2000/07/26 SUPPL-35(补充) Approval Labeling STANDARD
2000/02/11 SUPPL-37(补充) Approval Labeling STANDARD
1998/02/12 SUPPL-36(补充) Approval Manufacturing (CMC) PRIORITY
1996/03/29 SUPPL-34(补充) Approval Manufacturing (CMC) PRIORITY
1994/09/30 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
1989/01/27 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
1986/06/12 SUPPL-31(补充) Approval Manufacturing (CMC) PRIORITY
1986/01/31 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
1984/11/09 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
1984/08/03 SUPPL-24(补充) Approval Labeling
1984/01/09 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1983/07/05 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1982/09/27 SUPPL-19(补充) Approval Labeling
1982/09/27 SUPPL-18(补充) Approval Labeling
1982/06/18 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1981/12/17 SUPPL-21(补充) Approval Labeling
1980/10/14 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1980/10/06 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1980/06/06 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
1980/05/29 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1977/07/27 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
1976/12/08 SUPPL-12(补充) Approval Manufacturing (CMC) PRIORITY
1976/03/01 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1975/11/14 SUPPL-10(补充) Approval Manufacturing (CMC) PRIORITY
1965/12/16 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity and Type 4 - New Combination PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database